Cancer drug by Welwyn Garden City company approved
A GROUND-BREAKING new drug that is set to lead the fight against cancer has been developed by a company based in WGC.
Drug developer Antisoma has announced that a new “aptamer” drug, AS1411, has been granted “orphan” status in both the US and the European Union, for the treatment of Acute Myeloid Leukaemia.
It means the company will have market exclusivity to develop the drug over the next 10 years in Europe, and seven years in the US.
Aptamer drugs are short pieces of DNA or RNA that target particular proteins. AS1411 is a DNA aptamer that targets nucleolin, a protein found on the surface of cancer cells.
“The work that is being done here in WGC is of international importance in the battle against Leukaemia,” said Hertfordshire MEP Richard Howitt, who paid a visit to the company’s laboratories at BioPark in Broadwater Road.
You may also want to watch:
“The cutting-edge research is benefiting not just the local area but the entire world. European approval means that we can now steam ahead with saving peoples’ lives.”
For more on this story, see this week’s Welwyn Hatfield Times, out tomorrow.
Most Read
- 1 Murder-suicide investigation in Welwyn Garden City
- 2 Councillor disappointed as BioPark appeal confirmed
- 3 Grant Shapps suddenly cancels constituency event amid fuel chaos
- 4 14 of the best places for a curry in Hertfordshire according to readers
- 5 Five hospitalised after Hatfield dog attack
- 6 Ed Sheeran announces 2022 stadium tour: How to get tickets
- 7 Two more acts added to Hatfield music festival's 'line-up of headliners' for 2022
- 8 University of Hertfordshire paedophile caught with more than 500 child abuse images
- 9 'So much for grassroots tennis' - Price hike at Gosling Sports Park sparks ire
- 10 New Local Plan timetable aims for summer deadline
